# US 2005/0239891 A1 · Use of citrulline within the framework of intestinal insufficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0239891 A1
- Document ID: US20050239891A1
- Status: Published application
- Kind: A1
- Application number: 10/885,574
- Filed: 2004-07-08
- Published: 2005-10-27
- Earliest claimed: 2003-07-08
- Inventors: Sylwia Osowska-Vincent; Christophe Moinard; Luc Cynober; Marie-Emmanuelle Le Guern; Bernard Hublot; Paul Bernasconi
- Web page: https://patentgrep.com/patent/US20050239891A1

## CPC

- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of L-citrulline (I) for the preparation of a medicament intended for the treatment of pathologies linked to an intestinal insufficiency.

## Claims

### Claim 1

The use of L-citrulline (1) for the preparation of a medicament intended for the treatment of pathologies linked to an intestinal insufficiency,

### Claim 2 (depends on 1)

The use of L-citrulline according to claim 1, for the preparation of a medicament intended to increase the concentration of L-arginine in the plasma when it is abnormally low in patients suffering from pathologies linked to an intestinal insufficiency.

### Claim 3 (depends on 1)

The use of L-citrulline according to claim 1, for the preparation of medicament intended for the treatment of the following pathologies:
short-bowel syndrome following an intestinal resection, in particular in the case of acute mesenteric ischaemia, thrombosis of the superior mesenteric vein, volvulus of small intestine and strangulated hernia, chronic intestinal pseudo-obstruction, radiation-damaged small intestine, Crohn's disease, nongranulomatous ulcerous jejuno-ileitis, abdominal traumatism,
celiac disease,
chronic inflammatory diseases of the intestine such as Crohn's disease and ulcerous rectocolitis,
intestinal insufficiency linked to ageing, or
intestinal insufficiency linked to irradiation.

### Claim 4 (depends on 1)

The use of L-citrulline according to claim 1, for the preparation of a pharmaceutical composition comprising, as active substance, L-citrulline, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable vehicle.

### Claim 5 (depends on 1)

The use of L-citrulline according to claim 1, for the preparation of a pharmaceutical composition characterized in that the unit L-citrulline dose is approximately 1 g to approximately 10 g, in particular approximately 5 g, for a dosage of approximately 0.05 g/kg/day to approximately 0.50 g/kg/day, in particular approximately 0.025 g/kg/day.

### Claim 6 (depends on 1)

The use of L-citrulline according to claim 1, for the preparation of a pharmaceutical composition presented in dry form or in the form of an aqueous solution.

### Claim 7 (depends on 1)

The use of L-citrulline according to claim 1, for the preparation of a pharmaceutical composition presented in a form which can be administered by the oral, intraperitoneal, enteral or parenteral route.

### Claim 8 (depends on 1)

The use of L-citrulline according to claim 1, for the preparation of a pharmaceutical composition also containing one or more other compounds intended for the treatment of intestinal insufficiency, such as glutamine, orithine, growth hormone, or somatomedin C.

### Claim 9 (depends on 8)

A pharmaceutical composition, characterized in that is comprises, as active substance, L-citrulline, or a pharmaceutically acceptable salt thereof, in combination with at least one other compound intended for the treatment of intestinal insufficiency, such as the compounds defined in claim 8, and with a pharmaceutically acceptable vehicle.

### Claim 10

A product comprising:
L-citrulline,
and at least one other compound intended for the treatment of intestinal insufficiency, as a combined preparation for simultaneous, separate or sequential use, in the treatment of intestinal insufficiency.
